The stock of Sangamo Therapeutics Inc. (NASDAQ:SGMO) increased by $0.36 on Tuesday to finish at $3.94, up 10.06 percent. The last five days have seen an average of 2,649,040 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$3.56. The average number of shares traded over the last 20 days was 2,022,625, while the average volume over the last 50 days totaled 1,722,578.
SGMO stock dropped -1.50% since last month. On 06/16/22, the company’s shares reached a one-month low of $3.12. The stock touched a high of $12.83 on 01/04/22, after rallying from a low of $3.12 in 52 weeks. The price of SGMO stock has declined by -47.47% or -$3.56 this year, reaching a new high 2 times. Still, the stock price is down -69.29% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
There have been 19 days since Sangamo Therapeutics Inc. (SGMO) last reported insider trading activity on Jun 03. On Jun 03, Director Markels John acquired 6,784 shares at $3.69 each. This transaction resulted in the insider spending $25,029. On Jun 01, PARKER H STEWART added 5,000 shares at a price of US$3.60. After the transaction, the insider now owns 48,700 shares. 10% Owner BIOGEN INC. had earlier sold 2,764 shares on Dec 28 for $8.51 a share. The transaction was completed for $23,522.
Beta for the stock is 1.54. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.76, the price-to-book (PB) ratio of 1.72.
For the three months ended March 30, Sangamo Therapeutics Inc.’s quick ratio was 2.90, while its current ratio was 2.90, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $294.04 million and revenue of $110.7 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SGMO’s return on assets (ROA) during the last 12 months has been -23.60%. There was a -48.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -45.20%.
According to Sangamo Therapeutics Inc.’s quarterly financial report for the quarter that ended March 30, it had $197.54 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $28.23 million, while revenues rose by 6.91% to $27.99 million. It was predicted that Sangamo Therapeutics Inc.’s quarterly earnings would be -$0.3, but it ended up being -$0.31, beating the consensus by 3.20%. EBITDA was -$40.16 million for the quarter. At the end of Sangamo Therapeutics Inc.’s most recent quarter ended March 30, its liabilities totaled 319.79 million, while its total debt was $48.08 million. Equity owned by shareholders amounts to $146.69 million.
Here’s a quick look at Sangamo Therapeutics Inc.’s (SGMO) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 57.09%, suggesting the stock is Neutral, with a 118.92% historical volatility rate.
The stochastic %K and %D were 47.93% and 35.29% respectively, while the average true range (ATR) was 0.32. Based on the 14-day stochastic reading of 67.77%, the RSI (14) reading is 52.16%. On the 9-day MACD Oscillator, the stock is at -0.06, and the 14-day reading is at -0.08.
Analysts have assigned Sangamo Therapeutics Inc. (SGMO) an Overweight rating. SGMO is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 7 others recommend it as a buy.
What is SGMO’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.40 and $25.00, with a median target price of $13.00. In analyzing these forecasts, the average price target given by analysts for Sangamo Therapeutics Inc. (SGMO) is $14.49.